Cargando…

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

OBJECTIVES: In this paper, we discuss leveraging cloud-based platforms to collect, visualize, analyze, and share data in the context of a clinical trial. Our cloud-based infrastructure, Patient Repository of Biomolecular Entities (PRoBE), has given us the opportunity for uniform data structure, more...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Grady, Nicholas, Gibbs, David L, Abdilleh, Kawther, Asare, Adam, Asare, Smita, Venters, Sara, Brown-Swigart, Lamorna, Hirst, Gillian L, Wolf, Denise, Yau, Christina, van 't Veer, Laura J, Esserman, Laura, Basu, Amrita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172495/
https://www.ncbi.nlm.nih.gov/pubmed/34095775
http://dx.doi.org/10.1093/jamiaopen/ooab038
_version_ 1783702541268156416
author O'Grady, Nicholas
Gibbs, David L
Abdilleh, Kawther
Asare, Adam
Asare, Smita
Venters, Sara
Brown-Swigart, Lamorna
Hirst, Gillian L
Wolf, Denise
Yau, Christina
van 't Veer, Laura J
Esserman, Laura
Basu, Amrita
author_facet O'Grady, Nicholas
Gibbs, David L
Abdilleh, Kawther
Asare, Adam
Asare, Smita
Venters, Sara
Brown-Swigart, Lamorna
Hirst, Gillian L
Wolf, Denise
Yau, Christina
van 't Veer, Laura J
Esserman, Laura
Basu, Amrita
author_sort O'Grady, Nicholas
collection PubMed
description OBJECTIVES: In this paper, we discuss leveraging cloud-based platforms to collect, visualize, analyze, and share data in the context of a clinical trial. Our cloud-based infrastructure, Patient Repository of Biomolecular Entities (PRoBE), has given us the opportunity for uniform data structure, more efficient analysis of valuable data, and increased collaboration between researchers. MATERIALS AND METHODS: We utilize a multi-cloud platform to manage and analyze data generated from the clinical Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL). A collaboration with the Institute for Systems Biology Cancer Gateway in the Cloud has additionally given us access to public genomic databases. Applications to I-SPY 2 data have been built using R Shiny, while leveraging Google's BigQuery tables and SQL commands for data mining. RESULTS: We highlight the implementation of PRoBE in several unique case studies including prediction of biomarkers associated with clinical response, access to the Pan-Cancer Atlas, and integrating pathology images within the cloud. Our data integration pipelines, documentation, and all codebase will be placed in a Github repository. DISCUSSION AND CONCLUSION: We are hoping to develop risk stratification diagnostics by integrating additional molecular, magnetic resonance imaging, and pathology markers into PRoBE to better predict drug response. A robust cloud infrastructure and tool set can help integrate these large datasets to make valuable predictions of response to multiple agents. For that reason, we are continuously improving PRoBE to advance the way data is stored, accessed, and analyzed in the I-SPY 2 clinical trial.
format Online
Article
Text
id pubmed-8172495
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81724952021-06-04 PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial O'Grady, Nicholas Gibbs, David L Abdilleh, Kawther Asare, Adam Asare, Smita Venters, Sara Brown-Swigart, Lamorna Hirst, Gillian L Wolf, Denise Yau, Christina van 't Veer, Laura J Esserman, Laura Basu, Amrita JAMIA Open Research and Applications OBJECTIVES: In this paper, we discuss leveraging cloud-based platforms to collect, visualize, analyze, and share data in the context of a clinical trial. Our cloud-based infrastructure, Patient Repository of Biomolecular Entities (PRoBE), has given us the opportunity for uniform data structure, more efficient analysis of valuable data, and increased collaboration between researchers. MATERIALS AND METHODS: We utilize a multi-cloud platform to manage and analyze data generated from the clinical Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL). A collaboration with the Institute for Systems Biology Cancer Gateway in the Cloud has additionally given us access to public genomic databases. Applications to I-SPY 2 data have been built using R Shiny, while leveraging Google's BigQuery tables and SQL commands for data mining. RESULTS: We highlight the implementation of PRoBE in several unique case studies including prediction of biomarkers associated with clinical response, access to the Pan-Cancer Atlas, and integrating pathology images within the cloud. Our data integration pipelines, documentation, and all codebase will be placed in a Github repository. DISCUSSION AND CONCLUSION: We are hoping to develop risk stratification diagnostics by integrating additional molecular, magnetic resonance imaging, and pathology markers into PRoBE to better predict drug response. A robust cloud infrastructure and tool set can help integrate these large datasets to make valuable predictions of response to multiple agents. For that reason, we are continuously improving PRoBE to advance the way data is stored, accessed, and analyzed in the I-SPY 2 clinical trial. Oxford University Press 2021-06-03 /pmc/articles/PMC8172495/ /pubmed/34095775 http://dx.doi.org/10.1093/jamiaopen/ooab038 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Research and Applications
O'Grady, Nicholas
Gibbs, David L
Abdilleh, Kawther
Asare, Adam
Asare, Smita
Venters, Sara
Brown-Swigart, Lamorna
Hirst, Gillian L
Wolf, Denise
Yau, Christina
van 't Veer, Laura J
Esserman, Laura
Basu, Amrita
PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
title PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
title_full PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
title_fullStr PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
title_full_unstemmed PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
title_short PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
title_sort probe the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
topic Research and Applications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172495/
https://www.ncbi.nlm.nih.gov/pubmed/34095775
http://dx.doi.org/10.1093/jamiaopen/ooab038
work_keys_str_mv AT ogradynicholas probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT gibbsdavidl probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT abdillehkawther probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT asareadam probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT asaresmita probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT venterssara probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT brownswigartlamorna probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT hirstgillianl probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT wolfdenise probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT yauchristina probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT vantveerlauraj probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT essermanlaura probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial
AT basuamrita probethecloudtoolkitfindingthebestbiomarkersofdrugresponsewithinabreastcancerclinicaltrial